Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 2017;377:13 de julio. [Ref.ID 101914]
2.Tiene citas relacionadas Cita con resumen
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob M, Nsouli I, Iyer P, Cartagena R, Srider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, for the Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13. [Ref.ID 93469]
3. Cita con resumen
Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster Jr HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT, for the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms. A randomized trial. JAMA 2011;306:1344-51. [Ref.ID 91218]
4.Tiene citas relacionadas
Andriole GL, Rittmaster RS. Dutasteride and prostate cancer. The authors reply. N Engl J Med 2010;363:794-5. [Ref.ID 89162]
5.Tiene citas relacionadas Cita con resumen
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, for the REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:192-202. [Ref.ID 88262]
6. Cita con resumen
Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorock PC, Gohagan JK, Berg CD, PLCO Project Team. Mortality results from a randomized prostate cancer screening-trial. N Engl J Med 2009;360:1310-9. [Ref.ID 87353]
7. Cita con resumen
McConnell JD, Roehrborn C G, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg L M, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell J W, Schenkman NS, Slawin KM, Smith JA, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98. [Ref.ID 68500]
8.
Goodnough LT, Monk TG, Andriole GL. Erithropoietin therapy. N Engl J Med 1997;336:933-8. [Ref.ID 31321]
9. Cita con resumen
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell J, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91. [Ref.ID 18275]
Seleccionar todas
 
 1 a 9 de 9